Was stereotactic body radiotherapy (SBRT) included in the STAMPEDE cohort, and what form of radiotherapy did patients receive?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

STAMPEDE Radiotherapy Details

The STAMPEDE trial did NOT include stereotactic body radiotherapy (SBRT); patients received conventional external beam radiotherapy (EBRT) to the prostate. 1

Form of Radiotherapy Used in STAMPEDE

The STAMPEDE cohort utilized standard-of-care conventional radiotherapy to the prostate, not SBRT. This is a critical distinction when interpreting the trial's results and applying them to clinical practice.

Key Technical Details:

  • Target: Prostate gland (primary tumor site)
  • Technique: Conventional fractionated external beam radiotherapy
  • Patient Population: Men with newly diagnosed metastatic prostate cancer
  • Stratification: Results were analyzed by metastatic burden (low vs. high)

Clinical Outcomes by Metastatic Burden:

Low metastatic burden patients (42% of cohort):

  • Prostate RT improved overall survival (HR = 0.64,95% CI 0.52-0.79, p < 0.001) 1
  • 156 deaths in SOC+RT vs. 202 in SOC alone
  • This represents the standard of care for this population

High metastatic burden patients (58% of cohort):

  • No survival benefit from prostate RT (HR = 1.11,95% CI 0.96-1.28, p = 0.164) 1
  • 386 deaths in SOC+RT vs. 375 in SOC alone

Important Clinical Caveats:

The evidence provided about SBRT 2, 3, 2, 3 pertains to spinal metastases, not primary prostate treatment. SBRT for spinal metastases achieves approximately 90% local control at 1 year and 54% complete pain response, but this is an entirely different clinical scenario than the STAMPEDE trial's intervention.

Do not conflate STAMPEDE's conventional prostate radiotherapy with SBRT for metastatic sites. The STAMPEDE trial specifically evaluated whether adding conventional RT to the primary prostate tumor improves outcomes in metastatic disease, finding benefit only in low-burden disease without quality of life detriment 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.